title: The L-dopa response in vascular parkinsonism.
abstract: OBJECTIVE
  To determine whether a positive L-dopa response in vascular parkinsonism (VP) is correlated with the presence of nigrostriatal pathology due to either vascular damage or neuronal cell loss.
  
  
  METHODS
  Seventeen patients with pathologically confirmed VP were selected from the pathological collection of the Queen Square Brain Bank for Neurological Disorders, and their L-dopa response during life was compared with the presence of macroscopic vascular damage in the nigrostriatal pathway and microscopic substantia nigra cell loss.
  
  
  RESULTS
  Ten of the twelve patients with a good or excellent response had macroscopic infarcts or lacunae caused by enlarged perivascular spaces in the basal ganglia or microscopic neuronal cell loss in the substantia nigra. In contrast, only one of the five patients with a moderate or no response had lacunae in the putamen, and none had lacunar infarcts or substantia nigra cell loss.
  
  
  CONCLUSIONS
  These results suggest that a substantial number of patients with clinically suspected VP may respond with benefit to dopaminergic therapy, especially those with lesions in or close to the nigrostriatal pathway.
authors.affiliation: Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, Queen Square, London, UK.
authors.forename: J C M
authors.initials: JC
authors.lastname: Zijlmans
authors.forename: R
authors.initials: R
authors.lastname: Katzenschlager
authors.forename: S E
authors.initials: SE
authors.lastname: Daniel
authors.forename: A J L
authors.initials: AJ
authors.lastname: Lees
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020144:Basal Ganglia Cerebrovascular Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D002544:Cerebral Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D003342:Corpus Striatum / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D004292:Dominance, Cerebral / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008833:Microcirculation / Q000187:drug effects / Q000473:pathology; D009434:Neural Pathways / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D009460:Neurologic Examination / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D013378:Substantia Nigra / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa